JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
A decade of SGLT2 inhibitors in cardiovascular science: a bibliometric review
Abstract
Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained significant attention in cardiovascular science due to their cardioprotective and Reno protective effects beyond glucose control. Over the past decade, research in this field has expanded rapidly. This study aims to conduct a bibliometric analysis of global research trends on SGLT2 inhibitors in cardiovascular diseases from 2014 to 2024, evaluating publication output, citation impact, influential contributors, keyword trends, and international collaboration networks.
Methods: A bibliometric analysis was performed using the Web of Science (WoS) Core Collection database, focusing on articles published between January 1, 2014, and December 31, 2024, within the “cardiac cardiovascular system” category. VOSviewer software was utilized to visualize author collaborations, institutional affiliations, keyword co-occurrence, and citation distributions.
Results: A total of 1,271 articles were analyzed. Research output has increased significantly, particularly after 2020, aligning with key clinical trials on SGLT2 inhibitors. The most prolific journals included Cardiovascular Diabetology, Journal of the American College of Cardiology, and European Journal of Heart Failure. Leading institutions such as Harvard Medical School, University of Toronto, and University of Groningen were identified as major contributors. Citation analysis highlighted high-impact studies on SGLT2 inhibitors’ cardiovascular and renal benefits. Keyword co-occurrence analysis showed that heart failure, diabetes mellitus, and renal protection were dominant themes. The United States, Germany, and China emerged as major players in global collaborations, shaping the research landscape.
Conclusion: The bibliometric findings suggest that research on SGLT2 inhibitors in cardiovascular diseases is rapidly evolving, with increasing global contributions and high-impact publications shaping clinical applications. Future studies should focus on long-term cardiovascular and renal outcomes, mechanistic insights, and comparative effectiveness research to further establish SGLT2 inhibitors’ role in cardiovascular medicine.

Keywords : SGLT2 inhibitors, cardiovascular diseases, heart failure, bibliometric analysis, citation impact

Download Article


1. Chen B, Wang X, Pan D, Wang J. Global trends and hotspots in the association between chronic kidney disease and cardiovascular diseases: a bibliometric analysis from 2010 to 2023. Cardiorenal Med. 2025;15(1): 1-20. doi:10.1159/000542441
2. Wang J, Su Y, Li Y, Su T, Li Y. A bibliometric analysis of research hotspots and frontiers in diabetes and cardiovascular disease comorbidity from 2005 to 2024. medRxiv. 2024;2024:9. doi.org/10.1101/ 2024.09.29.24314577
3. Chen L, Ma S, Hu D, et al. Bibliometric study of sodium glucose cotransporter 2 inhibitors in cardiovascular research. Front Pharmacol. 2020;11:561494. doi:10.3389/fphar.2020.561494
4. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome study. Diabetes Care. 2016;39(5):717-725. doi:10.2337/dc16-0041
5. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
6. Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine (Baltimore). 2019;98(49):e18245. doi:10.1097/MD. 0000000000018245
7. Pan R, He Y, Melisandre W, et al. Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases. Front Pharmacol. 2024;15: 1437760. doi:10.3389/fphar.2024.1437760
8. Cardoso R, Graffunder FP, Ternes CM, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100885. doi:10.1016/j.eclinm.2021.100933
9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
10. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081
11. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887
12. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
13. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts. 2020.02.004
14. Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237-1250. doi:10.1111/dom.13648
15. Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2021;26(2):1-10. doi:10.1007/s10741-021-10083-z
16. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res. 2012;9(2):117-123. doi: 10.1177/1479164112441190
17. Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1-10. doi:10.1159/ 000503919 </ol> </div> <p>
Article available in :
Volume 8, Issue 3, 2025
Page : 461-468
https://doi.org/10.32322/jhsm.1668518
Article Information
Received : 31 Mar 2025
Accepted : 05 May 2025
Published : 30 May 2025
Corresponding Author :

Ahmet Yılmaz: Department of Cardiology, Faculty of Medicine, Karamanoğlu Mehmetbey University, Karaman, Turkiye

[email protected]
Citation : Yılmaz A. A decade of SGLT2 inhibitors in cardiovascular science: a bibliometric review. J Health Sci Med. 2025;8(3):461-468.

Read: 6
Cited: 0
Download : 12
_Footer